Advertisements


Patent ruling positive for Celgene and Bristol-Myers, says Guggenheim

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 11th, 2019

Celgene: Timing The Switch To Bristol-Myers

Celgene: Timing The Switch To Bristol-Myers.....»»

Category: topSource: seekingalphaAug 8th, 2019

Bristol-Myers announces European Commission approval of Celgene acquistion

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 29th, 2019

Bristol-Myers announces positive CHMP opinion for Empliciti combination

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 26th, 2019

Bristol-Myers" Emplicit combination for myeloma granted positive CHMP opinion

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 26th, 2019

Eliquis, Orencia sales propel Bristol-Myers to strong second quarter

Bristol-Myers Squibb Co , which is set to buy biotechnology company Celgene Corp for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia......»»

Category: topSource: reutersJul 25th, 2019

Buy Celgene, Sell Bristol-Myers Squibb Ahead Of Merger Closing

Buy Celgene, Sell Bristol-Myers Squibb Ahead Of Merger Closing.....»»

Category: topSource: seekingalphaJul 24th, 2019

Earnings Outlook: Celgene, Bristol-Myers and AbbVie still to report earnings this week: Here’s what to expect

The biotech sector’s earnings kick off in earnest this week......»»

Category: topSource: marketwatchJul 23rd, 2019

Earnings Outlook: Biogen, Celgene, Bristol-Myers and AbbVie report earnings this week: Here’s what to expect

The biotech sector’s earnings kick off in earnest this week......»»

Category: topSource: marketwatchJul 22nd, 2019

Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down

Bristol-Myers (BMY) declines as it announces to sell Otezla to settle FTC concerns, while Opdivo fails in liver .....»»

Category: worldSource: nytJun 25th, 2019

Abbvie To Buy Allergan For $60 Billion In Latest Pharma Megadeal

Just months after Bristol-Myers Squibb and Celgene announced one of the biggest drug industry tie-ups in recent memory.....»»

Category: blogSource: zerohedgeJun 25th, 2019

Bristol-Myers Squibb Loses $6 Billion in Value on Celgene Deal Setback: Brainstorm Health

Bristol Myers surprised investors, announcing it would spin off Celgene's popular drug Otezla to address antitrust concerns. Happy Monday, readers! Bristol-Myers Squibb hasn’t exactly had a p.....»»

Category: europeSource: fortuneJun 24th, 2019

Bristol-Myers Slips As Regulatory Hiccups Delay Celgene Deal; Liver Cancer Study Faces Setback

Uncertainty over Bristol-Myers Squibb Co (NYSE: BMY)'s impending deal to acquire Celgene Corporation (NASDAQ: CELG) and an adverse clinical trial readout were dragging the shares of the large-cap pharma company lo read more.....»»

Category: blogSource: benzingaJun 24th, 2019

Bristol-Myers plans to divest Celgene"s psoriasis drug

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal......»»

Category: topSource: reutersJun 24th, 2019

UPDATE: Bristol-Myers offers update on liver cancer trial, to sell Otezla to hasten close of Celgene deal

Brist.....»»

Category: topSource: marketwatchJun 24th, 2019

Bristol to divest Celgene"s psoriasis treatment in FTC clearance push

Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC)......»»

Category: topSource: reutersJun 24th, 2019

Bristol-Myers to sell Otezla to address FTC concerns in pending merger with Celgene

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchJun 24th, 2019

Bristol-Myers plans Otezla sale to get FTC Celgene clearance

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 24th, 2019

Bristol-Myers plans Otezla sale to get FTC Celgene clearance

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 24th, 2019

Bristol-Myers offers update on liver cancer trial, to sell Otzela to hasten close of Celgene deal

Bristol-Myers Squibb Co. said Monday a late-stage study of its Opdivo as a treatment for a type of liver cancer failed to meet its main goals. The company said the Phase 3 study called CheckMate -459 evaluating Opdivo versus sorafenib as a .....»»

Category: topSource: marketwatchJun 24th, 2019

Bristol-Myers Squibb And Celgene - On The Path To A Valuable Combination

Bristol-Myers Squibb And Celgene - On The Path To A Valuable Combination.....»»

Category: topSource: seekingalphaJun 20th, 2019